
The FDA approves oral SERD giredestrant for ESR1-mutated breast cancer after a 62% risk cut, tying supply to testing ahead of a November 30, 2026 adjuvant decision.
Innovative equipment, analytical techniques, software, and modeling systems are improving the tableting process.
Innovative equipment, analytical techniques, software, and modeling systems are improving the tableting process.
Download
.
over 11 years ago
Assessing and Improving the Palatability of Pharmaceuticalsover 11 years ago
Analytical Techniques for Oral Solid Dosage Formulationover 11 years ago
Simplify Formulation With PATover 11 years ago
Boosting Solubility in Lipid-Based Formulationsover 11 years ago
Innovations in Solid Dosage Equipment





